Effectiveness of Rituximab in Severe Wegener’s Granulomatosis: Report of Two Cases and Review of the Literature
Joaquim Oristrell*, Guillermina Bejarano, Rosa Jordana, Manuel Monteagudo, Begoña Marí, Arnau Casanovas, Carles Tolosa
Identifiers and Pagination:Year: 2009
First Page: 94
Last Page: 99
Publisher ID: TORMJ-3-94
Article History:Received Date: 31/3/2009
Revision Received Date: 14/4/2009
Acceptance Date: 22/5/2009
Electronic publication date: 25/6/2009
Collection year: 2009
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener’s granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented.